The Bipartisan Colon
Menée sur trois cohortes indépendantes incluant au total 2 027 patients atteints d'un cancer colorectal métastatique et recevant une chimiothérapie de première ligne en combinaison ou non avec le bévacizumab, cette étude met en évidence une association entre la localisation de la tumeur et la survie globale des patients
Contrasting viewpoints are common today between those leaning toward the right and to the left wing. In this issue of the Journal, Loupakis et al. (1), have published a translational and clinico-pathologic report on the biological differences between metastatic colon cancers that arise from right- vs left-sided tumors. First, some caveats should be noted: 1) This study involves patients with metastatic disease. Whether the observed differences apply to primary resection of such tumors is unknown. 2) The publication represents a pooled analysis of one registry and two randomized trials involving chemotherapy with or without bevacizumab. As such, it could identify a predictive marker, but not prognostic outcomes, as there are no untreated control patients. 3) The analysis deals with a subset of “evaluable” patients in both the AVF2107 and NO16966 studies, though we do not know the criteria for this selection or whether some biases were introduced via this process. 4) As the investigators note, no statistical correction was made for multiple comparisons, …
Journal of the National Cancer Institute , éditorial en libre accès, 2015